Kinross Gold Corporation (NYSE:KGC) Q3 2019 Earnings Conference Call - Preliminary Transcript
Nov 07, 2019 • 08:00 am ET
Good day, ladies and gentlemen, and welcome to the Spectrum Pharmaceuticals First Quarter 2015 Earnings Conference Call.
I'd now like to introduce your host for today's conference call, Shiv Kapoor, Vice President of Strategic Planning and Investor Relations. Sir, you may now begin.
Thanks. Good afternoon and thank you all for joining us today for Spectrum's first quarter 2015 financial results conference call. I'm Shiv Kapoor, Vice President of Strategic Planning and Investor Relations for Spectrum Pharmaceuticals.
With me today are Dr. Raj Shrotriya, Chairman and CEO; Joe Turgeon, President and Chief Operating Officer; Kurt Gustafson, Chief Financial Officer; Dr. Lee Allen, Chief Medical Officer; Tom Riga, Chief Commercial Officer; and other senior members of Spectrum's management team.
Here is an outline of today's call.First, Dr. Raj Shrotriya will provide you with the highlights of the first quarter and discuss our overall direction and strategy. Kurt will then provide a summary of our first quarter financial performance. Following this, Joe will review the company's operations, and Dr. Allen will review the pipeline.
We will then open up the call to questions. Before I pass the call to Dr. Shrotriya, I would like to remind everyone that during this call, we will be making forward-looking statements regarding future events in Spectrum Pharmaceuticals, including statements about product sales, profits and losses, the safety, efficacy, development, time line and clinical results of our drug products and drug candidates that involve risks and uncertainties that could cause actual results to differ materially.
These risks are described in further detail in our reports filed with the Securities and Exchange Commission. These forward-looking statements represent the company's judgment as of the date of this conference call, May 7, 2015, and the company disclaims any intent or obligation to update these forward-looking statements. However, we may choose to update them, and if we do so, we will disseminate the updates to investing public. For copies of today's press release, historical press releases, 10-Ks, 10-Qs, 8-Ks and other SEC filings and other important information, please visit our website at www.sppirx.com. I now would like to hand the call over to Dr. Shrotriya.
Dr. Rajesh Shrotriya
Thank you, Shiv, and thank you, everyone for joining us this afternoon. We are looking forward to 2015 as it should be a pivotal year for several drugs in our pipeline. Today, I'd like to focus on our four most exciting pipeline assets; first, SPI-2012 remains our highest priority in the company. At our Analyst Day on 13th March, we shared the key Phase 2 data, which demonstrated impressive efficacy and safety of our compound. If approved, this drug will compete in a worldwide market currently over $6 billion annually. The Phase III protocols have been developed in collaboration with both US and European regulatory agencies, and we are now busy selecting investigators and qualifying sites at this time.
Secondly, I'm impressed with the clinical data with Poziotinib, an oral irreversible pan-HER inhibitor currently in Phase II trials. With best-in-class potential, we believe, poziotinib will